Skip to main content

Table 2 Relapse rate and rebound rate

From: Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial

Group   Treatment success relapse rebound
  n PASI-50 Never PASI-50 relapse No relapse rebound No rebound
CHM 7 6 (86 %) 1 (14 %) 1 (17 %) 5 (83 %) 0 (0 %) 6 (100 %)
Placebo 10 9 (90 %) 1 (10 %) 6 (67 %) 3 (33 %) 0 (0 %) 9 (100 %)
Total 17 15 2 7 8 0 15
  1. CHM Chinese herbal medicine
  2. PASI-50, PASI score decreases more than 50 % from baseline
  3. Relapse, loss of 50 % of PASI improvement from baseline in patients who have achieved treatment success (at least 50 % improvement in PASI score from baseline)
  4. Rebound, defined only for patients who achieved PASI-50, occurred when the improvement in the PASI score increased up to 25 % from the baseline PASI score
  5. There was no difference in the relapse rate between the two groups by Chi-square (odds ratio: 0.10; 95 % CI: 0.008, 1.288; P = 0.119)